Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejec… (NCT02690974) | Clinical Trial Compass
CompletedPhase 4
Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting
Canada302 participantsStarted 2016-03-08
Plain-language summary
The primary purpose of the study was to describe the tolerability of treatment with the optimal dose of LCZ696 (97 mg sacubitril / 103 mg valsartan bid), over six (6) months, in patients with heart failure with reduced ejection fraction (HFrEF) in Canada.
The study was also to describe the overall tolerability, effectiveness and safety of LCZ696 for the management of HFrEF over 12 months of treatment, as well as describe the patterns of LCZ696 up and down dose titrations occurring during the management of patients with HFrEF.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Written informed consent must be obtained before any assessment is performed.
✓. Age ≥ 18 years and ≤ 80 years.
✓. Males or females.
✓. Diagnosis of Heart Failure NYHA class II-III.
✓. Diagnosis of Heart Failure with reduced Ejection Fraction (LVEF =\< 40%) and NYHA class II or III.
✓. Stable on any dose of ACEI or ARB prior to enrolment in the study
✓. Stable on any dose of a beta-blocker prior to enrolment in the study.
✓. Eligible for treatment with LCZ696 as per Canadian product monograph.
Exclusion criteria
✕. Symptomatic hypotension and/or a SBP \< 100 mmHg at baseline visit.
✕. Estimated GFR \< 30 mL/min/1.73m\^2 as measured by the simplified Modification of Diet in Renal Disease (MDRD) formula at baseline visit.
What they're measuring
1
Percentage of Participants on LCZ696 200 mg Bid at Month 6
✕. Known history of angioedema related to previous ACEI or ARBs therapy, or history of hereditary or idiopathic angioedema.
✕. Requirement of concomitant treatment with both ACEIs and ARBs.
✕. Concurrent participation in other clinical trials or receiving other investigational drugs within 30 days of enrollment.
✕. Hypersensitivity to the active substances, sacubitril or valsartan, or to any of the excipients.
✕. Concomitant use of aliskiren-containing drugs in patients with diabetes mellitus (type 1 or type 2) or moderate to severe renal impairment (GFR \<60ml/min/1.73m\^2).
✕. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.